Charalambos Kaittanis

Charalambos Kaittanis

Auto-generated profile, based on publicly available information

Charalambos Kaittanis

Takeda Pharmaceutical Co. Ltd., Cambridge, MA 02142, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Journal of Hepatology
Verified
Journal Article
Open access
EGEd Gane
Ed Gane
YLYoung-Suk Lim
Young-Suk Lim
JKJae B. Kim
Jae B. Kim
VJVasant Jadhav
Vasant Jadhav
LSLing Shen
Ling Shen
MYMan-Fung Yuen
Man-Fung Yuen
Current treatment for chronic hepatitis B virus (cHBV) infection requires lifelong treatment. New therapy aimed towards HBV functional cure would represent a clinically meaningful treatment advancement. ALN-HBV and VIR-2218 (modified from ALN-HBV by Enhanced Stabilization Chemistry Plus technology reducing off-target, seed-mediated binding while maintaining on-target antiviral activity) are investigational RNAi therapeutics that target all major HBV transcripts. We report the safety of single doses of VIR-2218 and ALN-HBV in humanized mice, a cross-study comparison of single doses of VIR-2218 and ALN-HBV safety in human heathy volunteers (n=24 and n=49, respectively), and the antiviral activity of two monthly doses of 20, 50, 100, 200 mg of VIR-2218 (total n=24) vs. placebo (n=8) in participants with cHBV infection. In humanized mice, alanine aminotransferase (ALT) levels were markedly lower following administration with VIR-2218 compared with ALN-HBV. In healthy volunteers, posttreatment ALT elevations occurred in 28% of participants receiving ALN-HBV compared with none in those receiving VIR-2218. In participants with cHBV infection, VIR-2218 was associated with dose-dependent reductions in hepatitis B surface antigen (HBsAg). The greatest mean reduction of HBsAg at Week 20 in participants receiving 200 mg was 1.65 log IU/mL. The HBsAg reduction was maintained at 0.87 log IU/mL at Week 48. No participants had serum HBsAg loss or hepatitis B surface antibody seroconversion. VIR-2218 demonstrated an encouraging hepatic safety profile in preclinical and clinical studies as well as dose-dependent HBsAg reductions in patients with cHBV infection. These data support future studies with VIR-2218 as part of combination regimens with a goal of HBV functional cure. ClinicalTrials.gov Identifier: NCT02826018 and NCT03672188.

22 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HYHushan Yuan
Hushan Yuan
MWMoses Q. Wilks
Moses Q. Wilks
GFGeorges El Fakhri
Georges El Fakhri
MNMarc D. Normandin
Marc D. Normandin
CKCharalambos Kaittanis
Charalambos Kaittanis
LJLee Josephson
Lee Josephson
A key advantage of nanomaterials for biomedical applications is their ability to feature multiple small reporter groups (multimodality), or combinations of reporter groups and therapeutic agents (multifunctionality), while being targeted to cell surface receptors. Here a facile combination of techniques for the syntheses of multimodal, targeted nanoparticles (NPs) is presented, whereby heat-induced-radiolabeling (HIR) labels NPs with radiometals and so-called click chemistry is used to attach bioactive groups to the NP surface. Click-reactive alkyne or azide groups were first attached to the nonradioactive clinical Feraheme (FH) NPs. Resulting “Alkyne-FH” and “Azide-FH” intermediates, like the parent NP, tolerated 89Zr labeling by the HIR method previously described. Subsequently, biomolecules were quickly conjugated to the radioactive NPs by either copper-catalyzed or copper-free click reactions with high efficiency. Synthesis of the Alkyne-FH or Azide-FH intermediates, followed by HIR and then by click reactions for biomolecule attachment, provides a simple and potentially general path for the synthesis of multimodal, multifunctional, and targeted NPs for biomedical applications.

24 May 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
OSOscar J. Santiesteban
Oscar J. Santiesteban
CKCharalambos Kaittanis
Charalambos Kaittanis
JPJ. Manuel Perez
J. Manuel Perez
Just relax: The dissociation constants (KD) of various molecular interactions can be determined using a novel competition assay with binding magnetic relaxation nanosensors. In this assay, changes in the magnetic relaxation (MR) of an aqueous suspension of the nanosensors facilitate the fast determination of KD values by using nanomolar protein concentrations (see picture).

8 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMegha Subramanian
Megha Subramanian
JMJames McIninch
James McIninch
IZIvan Zlatev
Ivan Zlatev
MSMark K Schlegel
Mark K Schlegel
CKCharalambos Kaittanis
Charalambos Kaittanis
VJVasant Jadhav
Vasant Jadhav
Adeno-associated virus (AAV)-based gene therapy could be facilitated by the development of molecular switches to control the magnitude and timing of expression of therapeutic transgenes. RNA interference (RNAi)-based approaches hold unique potential as a clinically proven modality to pharmacologically regulate AAV gene dosage in a sequence-specific manner. We present a generalizable RNAi-based rheostat wherein hepatocyte-directed AAV transgene expression is silenced using the clinically validated modality of chemically modified small interfering RNA (siRNA) conjugates or vectorized co-expression of short hairpin RNA (shRNA). For transgene induction, we employ REVERSIR technology, a synthetic high-affinity oligonucleotide complementary to the siRNA or shRNA guide strand to reverse RNAi activity and rapidly recover transgene expression. For potential clinical development, we report potent and specific siRNA sequences that may allow selective regulation of transgenes while minimizing unintended off-target effects. Our results establish a conceptual framework for RNAi-based regulatory switches with potential for infrequent dosing in clinical settings to dynamically modulate expression of virally-delivered gene therapies.

18 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TLTalakad Goolaiah Lohith
Talakad Goolaiah Lohith
CKCharalambos Kaittanis
Charalambos Kaittanis
ABAnthony Belanger
Anthony Belanger
SAShin Hye Ahn
Shin Hye Ahn
PSPhil Sandoval
Phil Sandoval
PMPaul McQuade
Paul McQuade
Success of gene therapy relies on the durable expression and activity of transgene in target tissues. In vivo molecular imaging approaches using positron emission tomography (PET) can non-invasively measure magnitude, location, and durability of transgene expression via direct transgene or indirect reporter gene imaging in target tissues, providing the most proximal PK/PD biomarker for gene therapy trials. Herein, we report the radiosynthesis of a novel PET tracer [18F]AGAL, targeting alpha galactosidase A (α-GAL), a lysosomal enzyme deficient in Fabry disease, and evaluation of its selectivity, specificity, and pharmacokinetic properties in vitro. [18F]AGAL was synthesized via a Cu-catalyzed click reaction between fluorinated pentyne and an aziridine-based galactopyranose precursor with a high yield of 110 mCi, high radiochemical purity of >97% and molar activity of 6 Ci/µmol. The fluorinated AGAL probe showed high α-GAL affinity with IC50 of 30 nM, high pharmacological selectivity (≥50% inhibition on >160 proteins), and suitable pharmacokinetic properties (moderate to low clearance and stability in plasma across species). In vivo [18F]AGAL PET imaging in mice showed high uptake in peripheral organs with rapid renal clearance. These promising results encourage further development of this PET tracer for in vivo imaging of α-GAL expression in target tissues affected by Fabry disease.

14 February 2025 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
CKCharalambos Kaittanis
Charalambos Kaittanis
HKHyunjung Kim
Hyunjung Kim
TTTyler Teceno
Tyler Teceno
YPYoann Petibon
Yoann Petibon
AKAshley Knight
Ashley Knight
PMPaul McQuade
Paul McQuade
Changes in metabolism are associated with several prevalent and rare diseases, like Hunter syndrome (MPS II). These alterations result in changes in mitochondrial function, therefore having non-invasive imaging biomarkers to detect this pathophysiological hallmark is a key objective of translational medicine. Here we report the synthesis and in vivo evaluation of the [18F]berberine analogue ([18F]BEAN), in both wildtype animals and a mouse model of Hunter's disease. PET/CT imaging revealed that [18F]BEAN could detect mitochondrial dysfunction in the heart, liver, and brain of Hunter's disease (Ids KO) mice. These data suggest that [18F]BEAN may be a viable translational PET biomarker for the imaging of diverse pathologies that have impaired mitochondrial function.